Mammalian Selenoprotein Differentially Expressed in Tumor Cells
Description of Invention:
This application describes the identification, cloning, and sequencing of a human
protein which contains selenium. A murine homolog has also been identified. The gene encoding the protein has been localized to the short arm of chromosome 1 at 1p31. Early work indicates that levels of the protein and/or mRNA are decreased in prostate, liver, ovarian and fallopian tube cancers and in lymphoma. Thus, levels of the protein or mRNA may be useful clinically as diagnostic or prognostic tools. The fact that other selenium proteins are known to be involved in the immunological response and the fact that this protein was originally detected in T cells leads to a hypothesis that the protein may play a role in the immunological response. Antibodies and tools for expressing the protein recombinantly may be useful in conducting further research on the functionality of this protein. This selenoprotein may potentially mediate a chemopreventative effect of selenium in prostate cancer.
Patent Status:
DHHS Reference No. E-011-1998/0 --
U.S Patent No. 6,849,417 issued 21 Feb 2005
U.S. Patent Application No. 10/919,554 filed 16 Aug 2004
Relevant Publication: This research has been published, in part, in J. Biol. Chem. 1998 Apr 10; 272(15):
8910-15.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics Cancer -Research Materials
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
